Verapamil Shortage: What Providers and Prescribers Need to Know in 2026

Verapamil remains a cornerstone therapy for supraventricular arrhythmias, hypertension, vasospastic angina, and cluster headache prophylaxis. Supply disruptions — particularly for extended-release oral formulations — have created clinical challenges for patients and providers alike. This guide consolidates current supply information, substitution guidance, and practical management strategies for prescribers navigating the 2026 landscape.

2026 Supply Status: A Formulation-Level Summary

As of 2026, verapamil is not listed on the FDA Drug Shortages Database for most oral formulations. However, localized supply disruptions continue at the pharmacy and regional wholesaler level. Here is a formulation-specific breakdown:

Immediate-release tablets (40, 80, 120 mg): Multiple generic manufacturers. Generally available nationally. Lowest supply risk.

Extended-release tablets (Calan SR 120, 180, 240 mg; generics from Glenmark): Following Mylan's June 2021 market exit, Pfizer (Calan SR) and Glenmark now cover most demand. Moderate risk of localized gaps.

Extended-release capsules (Verelan 120–360 mg; Verelan PM 100–400 mg): Fewer manufacturers; higher retail price. Some strengths intermittently unavailable. Higher supply risk, especially for specialized dosing needs in cluster headache management.

IV injection (2.5 mg/mL ampules and vials, Pfizer/Hospira): Currently available. Monitor institutional procurement closely — Hospira remains the primary supplier. A major shortage occurred in 2015–2016; no active shortage as of 2026.

Key Shortage Events That Shaped the Current Supply Landscape

Understanding the shortage history is essential for anticipating future risk:

2015–2016 IV Verapamil Shortage: Hospira, the sole supplier of verapamil injection, could not meet demand. The shortage lasted over a year and prompted conservation protocols in many institutions. Resolved when supply was stabilized.

June 2021 Mylan Discontinuation: Mylan discontinued all verapamil ER tablet formulations (120 mg, 180 mg, 240 mg in multiple NDC presentations), eliminating a major generic manufacturer from the oral ER market. This created downstream stocking disruptions lasting 12–18 months while alternative suppliers expanded capacity.

Clinical Substitution Guidance by Indication

When verapamil is unavailable, the appropriate alternative depends heavily on the indication. The following guidance is a clinical reference — individualize based on patient factors.

Hypertension

Diltiazem extended-release is the most pharmacologically similar substitution — it is also a non-dihydropyridine CCB with AV nodal effects. Dosing starts at 120–180 mg/day and is titrated to response. For patients where rate control is not the primary concern, dihydropyridine CCBs (amlodipine 5–10 mg daily) provide adequate antihypertensive effect with a better tolerability profile and wider availability. ACE inhibitors, ARBs, and thiazide diuretics remain evidence-based first-line alternatives per JNC and ACC/AHA guidelines.

Supraventricular Arrhythmias and Atrial Fibrillation Rate Control

Diltiazem (oral or IV) is the most appropriate substitution for rate control in SVT and AF when verapamil is unavailable. For patients with heart failure with reduced ejection fraction (HFrEF), non-dihydropyridine CCBs including both verapamil and diltiazem are generally contraindicated; beta-blockers (metoprolol succinate, carvedilol) or digoxin are preferred. Beta-blockers should not be combined with IV verapamil; do not initiate both agents simultaneously.

Vasospastic (Prinzmetal) and Stable Angina

Diltiazem extended-release is a direct substitute for vasospastic angina. For stable angina, amlodipine, long-acting nitrates, or ranolazine provide therapeutic alternatives depending on the clinical picture. Beta-blockers can be used for stable angina but may precipitate coronary spasm in vasospastic disease — avoid as monotherapy in Prinzmetal angina.

Cluster Headache Prophylaxis (Off-Label)

Verapamil at doses of 240–960 mg/day is considered first-line prophylaxis for episodic and chronic cluster headache per European Federation of Neurological Societies guidelines. When verapamil is unavailable, alternatives include lithium carbonate (requires serum monitoring), topiramate, and galcanezumab (Emgality), which holds FDA approval for episodic cluster headache. Short courses of systemic corticosteroids (prednisone taper) can bridge gaps. Note that the high doses used for cluster headache necessitate baseline ECG and monitoring for AV block and bradycardia.

Practical Strategies for Managing Patients During Supply Gaps

Prescribe early refills: For patients on chronic verapamil therapy, authorize refills at 75–80% of supply remaining. Document the clinical rationale for early refill in the chart.

Consider formulation switches: If Verelan PM is unavailable, standard Verelan (morning dosing) at the same daily dose is clinically reasonable for most patients, though the pharmacokinetic profile differs slightly.

Direct patients to medfinder: Rather than having your staff call pharmacies, direct patients to medfinder.com/providers — a tool that calls pharmacies on the patient's behalf and reports back by text on which ones have their prescription in stock.

Document substitution carefully: When transitioning patients to a therapeutic alternative, document the supply shortage as the clinical reason and monitor for therapeutic equivalence.

Resources for Monitoring Verapamil Supply

FDA Drug Shortages Database: accessdata.fda.gov/scripts/drugshortages

ASHP Drug Shortage Resource Center: ashp.org/drug-shortages

medfinder for providers: medfinder.com/providers

For a practical guide to helping your patients navigate verapamil availability, see: How to Help Your Patients Find Verapamil in Stock: A Provider's Guide.